Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 28, 2009

J&J Pays Crucell $442.35M as Part of Collaboration to Develop Universal Flu Products

  • Johnson and Johnson (J&J) is paying €301.8 million (roughly $442.35 million) for an 18% equity stake in Crucell as part of a collaboration related to mAbs and vaccines against influenza and other diseases. The deal, under which Crucell will work with J&J’s Ortho-McNeil-Janssen Pharmaceuticals, also includes development milestones and royalty payments.

    Ortho-McNeil will have commercialization rights to resulting products worldwide except the EU and certain other European countries where Crucell will hold commercialization rights.  The partnership will focus initially on a universal mAb product called flu-mAb for preventing and treating flu. Additional projects will encompass a universal influenza vaccine and mAbs and/or vaccines against up to three other infectious and noninfectious disease targets.

    The joint flu-mAB program aims to develop a universal product against all influenza A strains including seasonal and pandemic H1N1 and the avian H5N1 strain. Responsibility for development will be shared between Crucell and the Ortho-McNeil business or its affiliates.

    The flu-mAb part of the collaboration will in part be funded by Crucell’s recently won U.S. NIH contract to develop mAb-based products against seasonal and pandemic flu. The contract, announced in August, provides for NIH funding of up to $40.7 million, with additional options worth another $28.4 million, triggered at the NIH’ discretion.

    Additionally, Crucell has discovered influenza antibodies and will be responsible for R&D of these candidates and any new antibodies discovered through the collaboration through to Phase IIa trials. Ortho-McNeil will then take over further development.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »